SG11201908056QA - Anti-par2 antibodies and uses thereof - Google Patents
Anti-par2 antibodies and uses thereofInfo
- Publication number
- SG11201908056QA SG11201908056QA SG11201908056QA SG11201908056QA SG11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA
- Authority
- SG
- Singapore
- Prior art keywords
- building
- cambridge
- milstein
- international
- granta park
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472462P | 2017-03-16 | 2017-03-16 | |
| US201862637766P | 2018-03-02 | 2018-03-02 | |
| PCT/EP2018/056776 WO2018167322A1 (en) | 2017-03-16 | 2018-03-16 | Anti-par2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908056QA true SG11201908056QA (en) | 2019-09-27 |
Family
ID=61827709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908056QA SG11201908056QA (en) | 2017-03-16 | 2018-03-16 | Anti-par2 antibodies and uses thereof |
Country Status (30)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE |
| CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| MA49886A (fr) * | 2017-03-16 | 2020-06-24 | Medimmune Ltd | Anticorps anti-par2 et leurs utilisations |
| US12214216B1 (en) | 2019-10-16 | 2025-02-04 | Helen Feng | Photon enhanced bone growth system and method |
| AU2021328375A1 (en) * | 2020-08-18 | 2023-04-13 | Cephalon Llc | Anti-PAR-2 antibodies and methods of use thereof |
| GB202204159D0 (en) | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| AU2024212070A1 (en) | 2023-01-25 | 2025-07-31 | Medimmune Limited | Migraine therapy |
| WO2025172573A1 (en) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
| WO2025191185A1 (en) | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US20070053911A1 (en) * | 2003-03-11 | 2007-03-08 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8440627B2 (en) * | 2004-11-04 | 2013-05-14 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| CL2008001887A1 (es) * | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| AR070911A1 (es) * | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| WO2009139822A1 (en) | 2008-05-01 | 2009-11-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| WO2010017086A1 (en) * | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Effectors of par-2 activation and their use in the modulation of inflammation |
| HUE051130T2 (hu) * | 2008-08-07 | 2021-03-01 | Idexx Lab Inc | Eljárások szimmetrikus dimetilarginin kimutatására |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| NZ602220A (en) | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| NZ704771A (en) * | 2012-08-13 | 2018-02-23 | Regeneron Pharma | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| EP3160996B1 (en) | 2014-06-30 | 2022-06-08 | Merck Patent GmbH | Anti-tnfa antibodies with ph-dependent antigen binding |
| MA49886A (fr) * | 2017-03-16 | 2020-06-24 | Medimmune Ltd | Anticorps anti-par2 et leurs utilisations |
-
2018
- 2018-03-16 MA MA049886A patent/MA49886A/fr unknown
- 2018-03-16 EP EP25204633.9A patent/EP4681726A3/en active Pending
- 2018-03-16 WO PCT/EP2018/056776 patent/WO2018167322A1/en not_active Ceased
- 2018-03-16 JP JP2019549512A patent/JP7222901B2/ja active Active
- 2018-03-16 KR KR1020197030092A patent/KR102711884B1/ko active Active
- 2018-03-16 RS RS20251336A patent/RS67581B1/sr unknown
- 2018-03-16 FI FIEP18714185.8T patent/FI3596125T3/fi active
- 2018-03-16 HR HRP20251643TT patent/HRP20251643T1/hr unknown
- 2018-03-16 EP EP18714185.8A patent/EP3596125B1/en active Active
- 2018-03-16 ES ES18714185T patent/ES3056721T3/es active Active
- 2018-03-16 CN CN201880018128.7A patent/CN110446720B/zh active Active
- 2018-03-16 NZ NZ757915A patent/NZ757915A/en unknown
- 2018-03-16 US US15/923,374 patent/US10836822B2/en active Active
- 2018-03-16 LT LTEPPCT/EP2018/056776T patent/LT3596125T/lt unknown
- 2018-03-16 IL IL269134A patent/IL269134B2/en unknown
- 2018-03-16 DK DK18714185.8T patent/DK3596125T3/da active
- 2018-03-16 CA CA3055251A patent/CA3055251A1/en active Pending
- 2018-03-16 SI SI201831278T patent/SI3596125T1/sl unknown
- 2018-03-16 CR CR20190417A patent/CR20190417A/es unknown
- 2018-03-16 AU AU2018235031A patent/AU2018235031B2/en active Active
- 2018-03-16 BR BR112019018752-9A patent/BR112019018752A2/pt unknown
- 2018-03-16 MX MX2019010802A patent/MX2019010802A/es unknown
- 2018-03-16 UA UAA201910275A patent/UA125757C2/uk unknown
- 2018-03-16 PT PT187141858T patent/PT3596125T/pt unknown
- 2018-03-16 TW TW107109179A patent/TWI788332B/zh active
- 2018-03-16 SG SG11201908056QA patent/SG11201908056QA/en unknown
- 2018-03-16 PL PL18714185.8T patent/PL3596125T3/pl unknown
-
2019
- 2019-09-11 ZA ZA2019/06004A patent/ZA201906004B/en unknown
- 2019-09-13 CL CL2019002626A patent/CL2019002626A1/es unknown
- 2019-09-13 PH PH12019502087A patent/PH12019502087A1/en unknown
- 2019-10-03 CO CONC2019/0010975A patent/CO2019010975A2/es unknown
-
2020
- 2020-09-29 US US17/035,956 patent/US11591389B2/en active Active
-
2021
- 2021-10-27 AU AU2021257983A patent/AU2021257983B2/en active Active
-
2023
- 2023-02-03 JP JP2023015469A patent/JP2023055895A/ja active Pending
- 2023-02-07 US US18/165,614 patent/US20230242639A1/en not_active Abandoned
-
2025
- 2025-03-18 JP JP2025043151A patent/JP2025102812A/ja active Pending
- 2025-05-27 AU AU2025203947A patent/AU2025203947A1/en active Pending
- 2025-09-19 US US19/334,502 patent/US20260078180A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201809793UA (en) | Tl1a antibodies and uses thereof |